Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New vitamin D-based CYP24 inhibitors and their use claimed by Johns Hopkins U. and Cytochroma

Feb. 4, 2004

Novel antiangiogenic agents covered by Pfizer patent

Feb. 4, 2004

Novuspharma team identifies new VEGF production inhibitors

Feb. 4, 2004

Novel PARP inhibitors prepared and tested at Pfizer

Feb. 4, 2004

Department of Defense award for vaccine technology development at Generex

Feb. 3, 2004

Photodynamic therapy in combination with DMXAA shows promising therapeutic advantages

Feb. 3, 2004

Pfizer team presents novel GnRH antagonists in a recent patent

Feb. 3, 2004

Merck presents novel KSP inhibitors with utility in cancer therapy

Feb. 3, 2004

Cerus acquires mesothelin rights from Johns Hopkins University

Feb. 2, 2004

New phase I trial for RSR-13 in locally advanced NSCLC

Feb. 2, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...